Classical swine fever

Seek Labs Announces Successful Completion of African Swine Fever Virus In Vivo Trial Utilizing CRISPR-based Treatments

Retrieved on: 
Monday, May 6, 2024
Research, Genetics, Clinical Trials, Other Health, Biotechnology, Health, Agriculture, Natural Resources, Science, Other Science, Mortality, African swine fever virus, Viral disease, CRISPR, Gene targeting, Hope, White, Chicken, Synthetic control method, Blood, ASF, Classical swine fever, Cas, ELISA, Animal, Survival, Litopenaeus, Infection, Doctor of Philosophy, Disease, ASFV, Real-time, Food security, Viral load, Food, Seek, H5N1, Genome, Candidate, Viral, Pharmacy, Injection, WSSV, Medication, Vaccine

Seek Labs, a healthcare innovations company developing next-generation point-of-care molecular diagnostic systems and novel CRISPR-based gene therapies, announced today the successful completion of a therapeutic trial using innovative CRISPR-based technologies to target the African Swine Fever Virus (ASFV) in pigs.

Key Points: 
  • Seek Labs, a healthcare innovations company developing next-generation point-of-care molecular diagnostic systems and novel CRISPR-based gene therapies, announced today the successful completion of a therapeutic trial using innovative CRISPR-based technologies to target the African Swine Fever Virus (ASFV) in pigs.
  • The trial, which aimed to replicate and expand an earlier trial, demonstrated pigs infected with ASFV and treated with Seek Labs’ CRISPR-based systems survived longer than untreated infected pigs.
  • With no available treatments for African Swine Fever, this is a breakthrough discovery.
  • Seek Labs’ work represents a beacon of hope for the swine industry and underscores the transformative potential of CRISPR-based technology in global healthcare.

The World Market for Veterinary Diagnostics, 7th Edition - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 6, 2024
Veterinary, Health, Seventh Edition, Row, PRRS, Infection, Betaarterivirus suid 1, BVD, Clinical chemistry, Bovine viral diarrhea, Animal, IVD, Classical swine fever, TGE, Pet, Vaccine

The "World Market for Veterinary Diagnostics, 7th Edition" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "World Market for Veterinary Diagnostics, 7th Edition" report has been added to ResearchAndMarkets.com's offering.
  • Despite various challenges, the veterinary diagnostics market has shown consistent growth and is forecasted to continue on this trajectory.
  • The World Market for Veterinary Diagnostics, 7th Edition meticulously examines the global veterinary diagnostics market, focusing on two key components: companion animal (pets) diagnostics and food animal diagnostics.
  • The report provides a comprehensive analysis of major veterinary disease markets, offering insights into overall market performance and development.

The World Market for Veterinary Diagnostics 2021-2026: Featuring Key Players IDEXX, Thermo Fisher Scientific, Heska Corporation and Zoetis - ResearchAndMarkets.com

Retrieved on: 
Monday, March 7, 2022
Pets, Consumer, TGE, Betaarterivirus suid 1, Infection, Classical swine fever, Journal of Veterinary Diagnostic Investigation, Country, Magic: The Gathering core sets, 1993–2007, PRRS, Severe acute respiratory syndrome, Immunoassay, BVD, Molecular diagnostics, Row, Bovine viral diarrhea, Transmissible spongiform encephalopathy, Clinical chemistry, Companion, Vaccine, Medical device, Pet, Hematology, Growth, Food Animal Concerns Trust

The "The World Market for Veterinary Diagnostics, 5th Edition " report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The World Market for Veterinary Diagnostics, 5th Edition " report has been added to ResearchAndMarkets.com's offering.
  • The World Market for Veterinary Diagnostics, 5th Edition examines the worldwide veterinary diagnostics market through the performance of its two component markets of companion animal and food animal diagnostics.
  • The report provides an analysis of major veterinary disease markets as well as overall market performance and development.
  • Total Global Animal Diagnostic Testing Market, 2021-2026 (in millions $ at manufacturer level)
    Global Veterinary Diagnostic Testing Market Share by Region (%) 2021 (US, Europe, Asia Pacific, RoW)
    Food Animal Diagnostics Market by Infectious Disease (Bovine Viral Diarrhea [BVD], Classical Swine Fever [CSF], Enzootic Bovine Leukosis [EBL], Infectious Bovine Tracheitis [IBR], Porcine Coronavirus Diseases [PEDv, PDCoV, TGE], Porcine Reproductive and Respiratory Syndrome [PRRS], Pseudorabies/Aujeszky's, Transmissible Spongiform Encephalopathies [TSEs], Other) (% and $ millions) 2021
    The World Market for Veterinary Diagnostics, 5th Edition contains the following market data points for both the food animal and companion animal segments:
    Global Animal Diagnostic Testing Market by Animal Segment, 2021-2026 (in millions $ at manufacturer level)
    Veterinary Companion Diagnostics Market Segmentation 2021 (Companion Animal: Clinical Chemistry, Infectious disease, Hematology, Other Analyzers, Non-infect Immunodiagnostics, Molecular, Other Testing, Total; Food Animal: Immunodiagnostic Test Kits, Molecular Diagnostics, Clinical Chemistry, Other Infectious Disease Test Reagents, Total) ($million; %)
    Market Size and Growth for United States Diagnostic Testing Market, 2021-2026 ($millions)
    Market Size and Growth for European Diagnostics Testing Market, 2021-2026 ($millions)
    Market Size and Growth for Asia Pacific Diagnostic Testing Market, 2021-2026 ($millions)
    Asia Pacific Diagnostic Testing by Country Percent 2018 (Japan, Philippines, China, India, Others)
    Market Size and Growth for Rest of World Diagnostic Testing Market, 2021-2026 ($millions)
    RoW Companion Animal Diagnostic Testing by Country Percent 2021 (Companion Animal: Canada, Australia, Brazil, Mexico, Others; Food Animal: Canada, Brazil, Mexico, Others)

iBio Reports Fiscal Second Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, February 14, 2022
Webcast, Annual general meeting, Glycosylation, NYSE American, Calendar, Vaccine, Infection, Classical swine fever, Regulation of tobacco by the U.S. Food and Drug Administration, Data analysis, Capital, Maintenance, Reverse stock split, Norwich Pharma Services, Chief executive officer, Company, G&A, SEC, University of Texas Southwestern Medical Center, IL-2, Target, Compliance, Protein, Sale, Partnership, Bioprocess, Research, Hydroponics, Discovery, Texas A&M University, Risk, IND, Biopharmaceutical, Cancer, Marketing, Food security, Drug discovery, Severe acute respiratory syndrome coronavirus 2, Program, GLOBE, NYSE, Drug development, Food, Time, CEO, Solution, Immunity, Investigational New Drug, University, CDMO, Growth, Investment, Investor, CMO, Pharmaceutical industry, Video game, Online gambling, Renewable energy, COVID-19, Lead

BRYAN, Texas, Feb. 14, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (iBio or the Company), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System, today announces its financial results for the fiscal quarter ended December 31, 2021 and provides a corporate update.

Key Points: 
  • BRYAN, Texas, Feb. 14, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (iBio or the Company), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System, today announces its financial results for the fiscal quarter ended December 31, 2021 and provides a corporate update.
  • The Company anticipates the program will advance from Lead Optimization to IND-Enabling before the middle of calendar 2022.
  • As previously communicated, the Company expects revenue growth to return in the second half of fiscal 2022.
  • R&D and G&A expenses for the second quarter of fiscal 2022 increased 40% and 48%, respectively, over the comparable period in fiscal 2020.

World Swine Vaccines Market Report 2022: Focus on Products (Recombinant, Inactivated), & Type (Pseudorabies, Porcine Circovirus Type 2) - Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 21, 2022
Agriculture, Natural Resources, Health, Veterinary, Pharmaceutical, CAGR, Research, Technology, Vaccine, ICAR, PCV2, ALCO RS-2, Indian Veterinary Research Institute, Urbanization, COVID-19, Virus, Porcine reproductive and respiratory syndrome virus 2, Growth, Atmosphere, Farm, Disease, PRRS, Animal Health, DNA, Health, Infection, Betaarterivirus suid 1, Industry, Classical swine fever, IVRI, PPV, Diagnosis, Miniature pig, USD, Mutation, Bareilly, Prevalence, Foot, Indian Immunologicals Limited, Investment, Awareness, Aquaculture

The "Swine Vaccines Market Size, Share & Trends Analysis Report 2021-2028" has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Swine Vaccines Market Size, Share & Trends Analysis Report 2021-2028" has been added to ResearchAndMarkets.com's offering.
  • Porcine Parvovirus (PPV), Porcine Reproductive and Respiratory Syndrome (PRRS), Porcine circovirus type 2 (PCV2), Foot & Mouth Disease, Classical Swine Fever, and others remain to be extremely prevalent diseases in pig farms affecting economic losses.
  • The COVID-19 pandemic directly or indirectly impacted the business, results of operations, and financial conditions of market players.
  • In addition, the growing investments by key players to develop advanced products for better diagnosis are likely to propel market growth.

iBio Reports Fiscal First Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 15, 2021
CSF, Cancer, Industry, Therapy, University of Texas Southwestern Medical Center, Food, Growth, COVID-19, Artificial intelligence, Capsid, Tumor microenvironment, Regulation of tobacco by the U.S. Food and Drug Administration, Public expenditure, Webcast, U.S. Department of Defense Strategy for Operating in Cyberspace, Chief executive officer, CDMO, Ownership, Technology, Research, Injection, Element, Classical swine fever, GLOBE, Fiscal, Shareholder, Time, Marketing, Patient, Glycosylation, Compliance, Hydroponics, G&A, Investor, Infection, CEO, CGMP, Veterinary medicine, LLC, Sale, Protein, Vaccine, SEC, NYSE American, University, Maintenance, Government, University system, Investment, Partnership, Company, ESG, Awareness, Texas A&M University System, NYSE, IND, Fine chemical, Pharmaceutical industry, Animal

BRYAN, Texas, Nov. 15, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System®, today announces its financial results for the fiscal quarter ended September 30, 2021 and provides a corporate update.

Key Points: 
  • BRYAN, Texas, Nov. 15, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (iBio or the Company), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System, today announces its financial results for the fiscal quarter ended September 30, 2021 and provides a corporate update.
  • We are continuing to accelerate the execution of our growth strategy as we start our fiscal year 2022, said Tom Isett, Chairman & CEO of iBio.
  • Fiscal First Quarter and Recent Business Developments:
    In August 2021, iBio added to its pipeline by in-licensing an IL-2 sparing anti-CD25 antibody (IBIO-101) from RubrYc Therapeutics.
  • R&D and G&A expenses for the first quarter of fiscal 2022 increased 35% and 24%, respectively, over the comparable period in fiscal 2020.

African swine fever: devising an ‘exit strategy’ for affected countries

Retrieved on: 
Thursday, March 4, 2021
Animal virology, African swine fever virus, Influenza A virus subtype H1N1, Classical swine fever

EFSA has devised surveillance strategies that will help countries affected by African swine fever (ASF) to determine when the virus has stopped circulating among their wild boar populations.

Key Points: 
  • EFSA has devised surveillance strategies that will help countries affected by African swine fever (ASF) to determine when the virus has stopped circulating among their wild boar populations.
  • The scientific opinion recommends an exit strategy comprising two phases: a period of routine surveillance of wild boar (the screening phase) followed by a shorter period of intense surveillance (the confirmation phase).
  • Modelling demonstrated that:

    The opinion gives practical examples of how to apply the exit strategy to both large and small affected areas.

  • It also makes recommendations on the minimum monitoring periods needed to make the strategy effective.

Surging Feed Prices Will Challenge the U.S. Animal Protein Sector’s Recovery

Retrieved on: 
Thursday, December 10, 2020
Agriculture, Livestock, Animal virology, Meat industry, Food industry, Pig farming, Animal husbandry, African swine fever virus, Feed ratio, Classical swine fever, Meat

The higher feed costs come at a challenging time, as meat and poultry industry margins have been pressured by weak prices in 2020 due to COVID-19.

Key Points: 
  • The higher feed costs come at a challenging time, as meat and poultry industry margins have been pressured by weak prices in 2020 due to COVID-19.
  • Much of the increase in feed prices is being driven by Chinese demand for grain as it rebuilds its hog herd and overall animal protein supply after African Swine Fever (ASF) ravaged its herd the last couple of years.
  • The shortage of animal protein in China has drawn massive trade flows towards the worlds most populous country.
  • The impact of feed costs varies by species for several reasons, such as life cycle, feed ration, and components of other feed costs.

EFSA launches ‘Stop African swine fever’ campaign in south-east Europe

Retrieved on: 
Tuesday, September 1, 2020
Animal virology, African swine fever virus, Classical swine fever, ASF, European Food Safety Authority, Pig, Influenza A virus subtype H1N1, Health sciences, Health, Medical specialties, PEPPADEP

EFSA has begun a major campaign to raise awareness and help halt the spread of African swine fever in south-east Europe.

Key Points: 
  • EFSA has begun a major campaign to raise awareness and help halt the spread of African swine fever in south-east Europe.
  • The campaign is aimed at countries that in 2019 EFSA identified as collectively comprising a region of concern because of their proximity to countries where ASF is present.
  • Our campaign will complement the ongoing efforts of the European Commission and other international organisations to work towards the eradication of the disease in Europe.
  • African swine fever (ASF) is a viral disease that affects domestic pigs and wild boar.

Algenex and Global DX Announce Positive Evaluation of Herdscreen® ASFV Antibody Test for African Swine Fever

Retrieved on: 
Tuesday, July 21, 2020
Animal virology, African swine fever virus, Asfarviridae, ASF, Classical swine fever, Influenza A virus subtype H1N1

This new pen-side diagnostic test for African Swine Fever will be commercially available in 2020.

Key Points: 
  • This new pen-side diagnostic test for African Swine Fever will be commercially available in 2020.
  • The Herdscreen ASFV Test is a point-of-care rapid diagnostic test to identify pigs who have been exposed to the African Swine Fever Virus (ASFV).
  • It uses a carefully selected ASFV protein, which confers high sensitivity to the new test.
  • The Herdscreen ASFV Test has been considered appropriate as a front-line diagnostic test for African Swine Fever (ASF) in field conditions for both serum and blood samples.